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Introduction 
 
Pain pathways 
 
Peripheral fibers and spinal center 
 
The sensation of pain or nociception is the most distinctive of all the sensory 
modalities. By the definition of the International Association for the Study of Pain, “Pain is 
an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage”. Unlike other sensory modalities, it doesn‟t have a specialized sensory organ, and 
has an urgent and primitive quality, a quality responsible for the affective and emotional 
aspect of pain perception (Kandel et al. 2000). It serves an important function, namely to 
warn the body and prevent of further injury that should be avoided or treated. However, the 
reduction of pain is often necessary in the clinical practice, which requires an overall 
knowledge about the systems responsible for the mediation of this sensation. Nociception is 
defined as "the neural processes of encoding and processing noxious stimuli”, triggers a 
variety of autonomic responses, however it does not necessarily lead to the experience of 
pain (Loeser and Treede 2008). Perception is a product of the brain‟s abstraction and 
elaboration of sensory input (Fenton 2007). 
The nociceptive system can be divided into peripheral and central components. 
Most peripherally are the specialized sensory receptors, called nociceptors. A nociceptor is 
defined as “A (sensory) receptor preferentially sensitive to a noxious stimulus or to a 
stimulus which would become noxious if prolonged” (Merskey 1986). Nociceptors are free 
nerve endings and are widely found in the skin, mucosa, membranes, deep fascias, 
connective tissues of visceral organs, ligaments and articular capsules, periosteum, 
muscles, tendons, and arterial vessels, and may respond to three types of stimuli: 
mechanical, thermal (extremes of hot and cold), and chemical substances. Based upon the 
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connecting axon, there are two major peripheral pathways: the A-delta, and C-fiber 
mediated nociception. 
 - A-delta nociceptors respond to noxious thermal or mechanical stimuli and form 
small diameter (2.0 to 6.0 µm) myelinated afferents which propagate action potentials into 
the central nervous system (CNS) at a fast speed (15-30 m/s). Activity in these afferents is 
associated with „first‟ or „fast‟ pain sensations, which are often described as „severe‟ and 
„sharp‟.  
- C-fiber afferents can respond to all types of noxious stimuli (noxious mechanical, 
thermal or chemical). They form 0.4 to 1.2 µm wide unmyelinated, slow-conducting (0.5-2 
m/s) afferent fibers. Activity in the C-fibers is associated with the „second‟ or „slow‟ pain 
sensations which are often described as „dull‟ and „aching‟. These afferents are particularly 
sensitive to endogenous algesic chemicals resulting from cell damage, including potassium, 
serotonin (5-HT), bradykinin, histamine, prostaglandins, leukotrienes and substance P. 
(Table 1.) (Johnson 1997) 
 
 
Substance Source Effect on primary afferent fibers 
K+ Damaged cells Activation 
5-HT Platelets Activation 
Bradykinin Plasma kininogen Activation 
Histamine Mast cells Activation 
Prostaglandins Arachidonic acid – damaged cells Sensitization 
Leukotrienes Arachidonic acid – damaged cells Sensitization 
Substance P Primary afferents Sensitization 
Table 1. – Naturally occurring agents that activate or sensitize nociceptors (Fields 1987) 
 
The cell bodies of the peripheral nociceptive afferents are found in the dorsal root 
ganglia (DRG) of the spinal cord and in sensory ganglia of some cranial nerves (V, IX, X).  
Neurons in the DRG can be classified as A- and B-cells. A-cells in general are larger and 
seem to equal the number of myelinated fibers, while smaller B-cells probably transmit 
noxious information to the CNS via unmyelinated axons (Tandrup 2004). Three subtypes of 
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B-cells were identified. Sugiura et al. studied the different sensory modalities of 
morphologically defined subtypes of B-cells in the DRG. High threshold mechano- and 
mechanical cold nociception are linked to B1, polymodal nociception to B2 and cooling 
reception to the B3 subtypes (Sugiura et al. 1988). 
The central afferents of these ganglion cells enter the CNS by way of dorsal root to 
terminate in the spinal cord or by way of cranial nerves to end in the brainstem, where the 
initial stages of central processing occur. Recent evidence from human and animal studies 
has significantly expanded the understanding of pain perception and has demonstrated that 
a complex series of spinal and supraspinal structures are involved in pain (Fenton 2007). 
Intrinsic neurons of the dorsal horn (DH) promote the interaction of the afferent and 
efferent fibers, and are also responsible for their transfer to supraspinal structures. 
The dorsal horn of the spinal cord has been described as a layered structure, based on 
histological sections stained for Nissl substance. The grey matter of the spinal cord consists 
of 10 laminae, including 6 in the DH (Szentágothai and Réthelyi 2002). The laminae of the 
DH can be grouped into the superficial layers (laminae I and II or the marginal zone and 
substantia gelatinosa, respectively) and the deep layers (laminae III-IV-V or the nucleus 
proprius, lamina VI or the base of the DH, the lateral spinal nucleus, nucleus caudalis, and 
some regions around the central medullary canal - lamina X) (Willis, Jr. 1988). 
Nociceptive pathways in the DH spread out to different directions through various 
excitatory and inhibitory interneurons. In view of the reception and integration of the 
afferent stimulus, neurons in the DH can be classified as interneurons that can be divided 
into interlaminar and intrasegmental intralaminar types, having inhibitory or excitatory 
characteristics; and projecting neurons that directly transmit the information to supraspinal 
centers. There are two distinct types of projecting neurons, which respond to nociceptive 
information:  
- Nociceptive specific (NS) cells are predominantly found in lamina I, II (external), 
V and VI of the DH (Willis, Jr. 1988). The sources of input for these neurons are A-delta 
and C fibers. These neurons respond only to noxious input. When activated, NS cells 
rapidly transmit information onward to the brain. 
- Wide dynamic range (WDR) cells are found in laminae I, II (external), IV, V, 
VI, X and receive noxious input from A-delta and C nociceptors and also non-noxious 
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input from large diameter A-beta (touch) fibers. These A-beta fibers normally transmit 
information about non-noxious stimuli to produce touch sensations. The main characteristic 
of WDR cells is the capacity of coding for the stimulus intensity because they show 
increasing frequencies of response from innocuous to noxious stimulation. Because of the 
convergence of noxious and non-noxious fibers, this group also plays a fundamental role in 
the mechanisms of segmental suppression of pain. 
After the direct or indirect connections with the projection neurons, the axons of 
these central nociceptive transmission cells ascend to supraspinal centers at least along five 
central pathways. 
 
Central pathways 
 
- The spinothalamic and trigeminothalamic tracts are the most prominent, direct 
nociceptive pathways, connecting the spinal cord and trigeminal nuclei with the thalamus. 
These axons project nociceptive information from the body and the head respectively, 
primarily from the NS and WDR neurons in laminae I and V of the DH (but also from 
laminae II, IV, VI, VII, VIII and X). These fibers cross the midline, and ascend in the 
anterolateral white matter of the spinal cord. Nociceptive information is projected from the 
thalamus onward to the somatosensory cortex where the sensory dimensions of pain are 
processed. This will provide information relating to the intensity, quality and location of the 
noxious stimuli. 
Based on the origin and the model of projection of these fibers, three forms of 
afferences of the spinothalamic tract can be identified. One is the neospinothalamic 
pathway or ventral spinothalamic tract, which directly projects to nuclei of the lateral 
complex of the thalamus, involved in the sensory–discriminative component of pain.  
Another is the paleospinothalamic pathway, or dorsal spinothalamic tract, which 
projects to nuclei of the posterior medial and intralaminar complex of the thalamus, 
involved in the motivational–affective aspects of pain.  
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Finally, a monosynaptic spinothalamic pathway projecting directly to the medial 
central nucleus of the thalamus is involved in the affective component of the painful 
experience. 
 - The spino-reticulo-thalamic or spinoreticular tract comprises the axons of 
neurons in laminae V, VII and VIII and also in laminae I and X. In contrast to the 
spinothalamic tract, many of the axons do not cross the midline. It ascends in the 
anterolateral quadrant of the spinal cord and terminates in the reticular formation of 
medulla and pons, and after synapses it projects to the hypothalamus and the thalamus. This 
tract is involved in the motivational-affective characteristics, as well as the neuro-
vegetative responses to pain. The real functional importance of this tract is believed to be 
due to the connections established in the brainstem because the projections to the 
intralaminar nuclei of the thalamus are sparse and probably occur by means of collateral 
branches of the spinothalamic tract. This tract is also an important pathway for the 
modulation of nociceptive information by activating brain stem structures responsible for 
descending suppression. 
- The spinomesencephalic tract comprises the axons of neurons in laminae I, II IV, 
V, VI, VII, and X. It projects in the spinotectal bundle to the deep layers of the superior 
colliculus and to the periaqueductal grey matter (PAG). The activity of this tract as well as 
the spinothalamic tract, suffers inhibitory or excitatory influences from interneurons 
activated by collateral neurons of the spinocervical tract. The spinomesencephalic tract 
together with the sacral parasympathetic nucleus and collaterals of the spinoreticular tract 
also sends projections to the parabrachial nucleus (PBN) of the pons. Since neurons of the 
PBN project to the amygdala, the major component of the limbic system, this track is 
thought to contribute to the autonomic, cardiovascular, motivational and affective 
responses to pain. However, the afferences to the amygdala and other limbic structures do 
not occur exclusively through the PBN. Direct tracts from the spinal cord to the amygdala, 
lenticular nucleus, nucleus accumbens, septum, cingular, frontal and infralimbic cortex 
have also been described. For this reason, they are considered spinal–limbic pathways by 
some authors (Gauriau and Bernard 2002, Schaible and Grubb 1993, Willis and Westlund 
1997). 
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- The spino-cervico-thalamic tract arises from neurons in the lateral cervical 
nucleus, located in the lateral white matter of the upper two cervical segments. This nucleus 
receives input from the nociceptive neurons in laminae III and IV. Most axons in the tract 
cross the midline and ascend in the medial lemniscus of the brainstem to nuclei in the 
midbrain and to the ventroposterior lateral (VPL) and posteromedial nuclei (PM) of the 
thalamus. Some axons from the nociceptive neurons project through the dorsal columns of 
the spinal cord and terminate in the cuneate and gracile nuclei of the medulla. 
- The spinohypothalamic and trigeminal-hypothalamic tracts comprise axons of 
neurons in laminae I, V, (VIII) and X. They project supraspinally to the autonomic control 
centers in the hypothalamus and are thought to activate complex neuroendocrine and 
cardiovascular responses (Kandel et al. 2000). 
 
Brainstem 
 
Brainstem sites previously thought to be primarily involved in cardiovascular function 
and autonomic regulation also have been demonstrated to play a role in the modulation of 
spinal nociceptive transmission (Jones 1992, Kwiat and Basbaum 1992). 
The concept of nociceptive gating or descending control of pain has arisen more 
than 30 years ago (Melzack and Wall 1965). The authors have phrased that nociceptive 
information impinging upon the DH of the spinal cord from the skin, viscera and other 
tissues, is not automatically transferred to higher centers. According to our recent 
knowledge, this system can either inhibit or facilitate the activity of the ascending pain 
pathways. In this respect, mechanisms of both “descending inhibition” (DI) and 
“descending facilitation” (DF) must be recognized.  
Terminals of descending pathways originating in the rostral ventromedial medulla 
(RVM), locus coeruleus (LC), the nucleus tractus solitarius (NTS), the PBN, the dorsal 
reticular nucleus (DRT) interact with afferent fibers, interneurons and projection neurons in 
the DH. Actions at these sites, as a function of the influence of individual receptors upon 
cellular excitability, either suppress or enhance passage of nociceptive information to the 
above mentioned higher centers (Millan 2002). 
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The PAG is a key relay station in the processing of nociceptive and antinociceptive 
information in the CNS. Its ventral and ventrolateral regions are widely known as key 
stations in descending pathways that act to control nociceptive inputs in the DH (Pelegrini-
da-Silva et al. 2005). GABAergic antagonists, cannabinoids, and µ-opioid agonists all 
initiate brainstem-integrated, monoaminergic mechanisms of DI via actions in this 
structure. It receives sensory information from the spinoreticular tract, afferentation from 
pain-related cortical and subcortical areas, and is thought to represent the mechanisms 
whereby cortical and other inputs act to control the nociceptive „gate‟ in the DH (Anuradha 
et al. 2004, Rainville 2002). Anatomical and physiological studies conducted throughout 
the 1970s elucidated a major pathway from the PAG to the raphe magnus and adjacent 
reticular formation of the RVM and in turn from RVM to the DH. Direct links from the 
PAG to serotonergic and nonserotonergic (e.g. opioid) neurones of the RVM, as well as to 
the noradrenergic nucleus of the medulla, are important pathways for expression of its role 
in the modulation of descending controls. Also, a small population of fibers directly 
projects from the PAG to the trigeminal nucleus and the DH.  
Therefore the termination zone of many RVM axons within the superficial and deep 
layers of the DH matched the region where nociceptors terminated, suggesting that PAG 
and RVM modulate nociception, although they do not do so specifically or exclusively. 
Studies reveal that PAG and RVM are capable of altering numerous reactions and 
responses in addition to those associated with noxious stimulation (Mason 2005, Starowicz 
et al. 2007). Although the RVM receives direct sensory input, the activity of descending 
pathways originating therein is primarily modified by afferents from the PAG, PBN and 
NTS (Fields and Basbaum 1984, Fields and Basbaum 1999, Millan 1999). Based on 
functional characteristics, several contrasting classes of neurons have been recognized in 
the RVM. First, “OFF” cells are excited by opioids and inhibited by nociceptive input. 
They display a transient interruption in their discharge immediately prior to a nociceptive 
reflex and are thought to participate in the induction of DI. Second, “ON” cells are 
inhibited by opioids and excited by nociceptive input: they are thought to trigger DF (Fields 
et al. 1991, Fields and Basbaum 1999, Mason 1999, Zhuo and Gebhart 1992).  
The locus coeruleus (LC) is considered the main noradrenergic nucleus involved in 
the ascending and descending control of pain (Stamford 1995, Zhang et al. 1997). It 
 14 
receives its main inputs from the nucleus prepositus hypoglossi and from the PAG via the 
paragigantocellular nucleus of the ventromedial medulla. The LC sends a major pathway to 
the spinal cord, mainly to the DH. Acute impositions of high intensity noxious stimuli have 
been shown to increase the activity in the LC and the noradrenaline level in the DH 
(Chiang and Aston-Jones 1993, Crawley et al. 1979, Hong et al. 1993, Men and Matsui 
1994, Szot et al. 1993), while electrical stimulation here produced a selective inhibitory 
action on the discharge evoked by nociceptive cutaneous or visceral stimuli (Guo and Zhao 
2000, Liu et al. 2008, Margalit and Segal 1979, West et al. 1993). Under conditions of 
persistent noxious input, the potentiation of descending noradrenergic input to the DH is 
pronounced and plays a major role in the moderation of pain (Milne et al. 2001). 
 
Thalamus 
 
The thalamus has been long regarded as the key relay structure for the supraspinal 
receipt, integration and onward transfer of nociceptive information. The different 
projections to its nuclei and from them to the cortex define the functional circuitry of pain 
processing. It encodes information concerning the type, temporal pattern, intensity and 
topographic localization of pain. Further, it interlinks with cortical and limbic structures 
responsible for both the sensory-discriminative and emotional dimensions of pain (Millan 
1999). In the thalamus, two groups of nuclei are particularly important in the processing of 
nociceptive information: the lateral and medial nuclear groups. 
The lateral nuclear group comprises the ventroposteromedial nuclei (VPM), receiving 
input from the head through the trigemino-thalamic pathway, the ventroposterolateral 
(VPL) and the ventroposteroinferior (VPI) nuclei comprising afferentation from the body 
and limbs via the spinothalamic tract. Neurons in these nuclei respond to both thermal and 
mechanical stimuli and show a somatotopic organization. The receptor fields in VPI are 
larger than those in VPL and VPM, and connections of neurons here with the secondary 
somatosensory cortex (SII) suggest different forms of processing with respect to the 
sensory-discriminative and affective-cognitive aspects of pain. The VPL and the VPM as 
the main somatosensory relays process noxious and innocuous information of cutaneous, 
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muscular, articular and visceral origin. Through the interconnections of primary 
somatosensory cortex (SI), these nuclei are responsible for the localization and intensity of 
pain. Neurons of the VPL and VPM are predominantly of the WDR type, they contribute to 
the sensory-discriminative aspects of thermal, mechanical and tactile information, but 
through its interconnections with the prefrontal cortex, parabrachial region, amygdala, 
hypothalamus and PAG, they are also involved in the emotional and autonomic responses 
of pain. 
The medial nuclear group of the thalamus comprises the posterior complex, consisting 
of the pulvinar oral nucleus, posterior nucleus and the posterior ventromedial nucleus, as 
well as the dorsal medial, central lateral and the intralaminar nuclei of the thalamus (medial 
complex). These nuclei receive input mostly from neurons in laminae I and V of the DH 
through the spinothalamic tract, and laminae VII and VIII. These afferentations indicate 
that nuclei here play a central role in the integration of painful information. 
Interconnections of this group with the insular and cingulate cortex suggest that it 
contributes to the emotional and affective-cognitive components of pain. The posterior 
region of the thalamus receives nociceptive information from the spinal cord by both the 
spinothalamic and spinomesencephalic tracts and its output is to the anterior cingulate 
cortex, an area with a signal processing role in nociception. The medial complex has 
similar projections to these limbic centers, but also includes structures, such as the striatum 
and cerebellum, responsible for arousal and motor responses. 
 
Higher pain-related centers in the brain 
 
Along with the linearly organized pathway model, the idea of parallel and 
bidirectional (down-up and up-down) processing of nociception appears to be more in line 
with the recently acquired information by recent imaging techniques (PET, SPECT, fMRI) 
on the pain network in the brain (Treede and Lenz 2006). These techniques can provide 
indirect measures of local brain activity, and made it possible to produce maps representing 
changes in the cortex, during painful stimulation. 
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Neurons in several regions of the cerebral cortex respond selectively to nociceptive 
input. Although some experimenters have different results when comparing painful and 
non-painful conditions, some regions are widely agreed to contribute to nociception. They 
include principally the contralateral primary and secondary somatosensory cortices (SI and 
SII), the anterior cingulate cortex (ACC), the insular cortex (IC) and regions of the frontal 
cortex (Berman 1995). Considering afferences to thalamic nuclei and their cortical 
projections, two systems of nociceptive projections are distinguished, i.e., the lateral and 
medial systems.  
The lateral system participates directly in the sensory-discriminative attribution of 
nociception and involves thalamic nuclei projecting to NS and WDR neurons in SI and SII. 
Cell types are considered to code different modalities of nociception. Although they are 
both able to code the intensity of stimuli, this function seems to be related more to WDR 
neurons, whereas NS cells mainly act on the topographic localization of peripheral stimuli. 
In addition, nociceptive neurons located in the SII have been reported to code the painful 
stimulus in temporal terms (Timmermann et al. 2001, Treede et al. 1999). Since SI and SII 
cortices are interconnected with the posteroparietal area and the insular cortex through a 
cortico-limbic pathway, somatosensory information is associated with other sensory 
modalities and also with learning and memory. 
The medial nociceptive system has less defined projections from the medial region 
of the thalamus to SI, SII and also to limbic structures such as the IC and the ACC (Picard 
and Strick 1996). This system is considered to contribute to the motivational-affective 
component of pain, but participates in the sensory-discriminative circuitry as well. 
The ACC is part of the limbic system and is thought to be involved in processing 
the emotional component of pain. It receives anatomical projections from several sources, 
including the IC. The ACC is the most agreeable brain region activated in brain imaging 
studies of pain and pain-related activation is reported most consistently in the ventral part 
of the supracallosal ACC, in the dorso-caudal ACC, and occasionally in the perigenual area 
(Hsieh et al. 1996, Peyron et al. 2000, Price 2000). The supracallosal area may be involved 
more specifically when the afferent input is of somatic origin and has an intrinsic affective 
value, whereas the dorsal sector of the ACC may be involved when extrinsic, secondary 
affective value is attributed to stimuli, such as in cognitive studies (Rainville 2002). These 
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studies show that ACC is more directly involved in pain affect than in appreciating the 
sensory qualities of pain. Cingulotomy in patients suffering from intractable pain modifies 
emotional and behavioral reactions to pain, without impairing the ability to localize a 
painful stimulus (Ballantine et al. 1967, Foltz and White 1968).  
The IC receives direct projections from the the ventral and posterior medial thalamic 
nuclei, and processes information on the internal state of the body, thus contributing to the 
autonomic component to the overall pain response. Damage to large parts of IC has been 
found among patients with pain asymbolia (Berthier et al. 1988, Weinstein et al. 1955). 
Patients with this condition do not display behavior indicative of threat or intrusion in 
response to painful stimuli despite their capacity to still appreciate the sensory qualities of 
painful stimuli. The IC may therefore integrate the sensory, affective and cognitive 
components of nociception. 
The amygdala complex is a medial temporal lobe brain structure, which, as a part 
of the limbic system is generally believed to be involved in the neural substrates of 
emotion. The amygdala is directly linked to nociceptive centers in the spinal cord and 
brainstem through the spino-ponto-amygdaloid pathway from the pontine parabrachial area 
to the central nucleus of the amygdala (Bernard et al. 1996, Bernard and Besson 1990, 
Neugebauer and Li 2002). Apart from concerning the emotional components of pain, the 
amygdala might also be involved in learning the association between painful and neutral 
stimuli, to be able to avoid previously met aversive conditions (Buchel et al. 1999). Its 
central nucleus has direct connections with the PAG, the PBN, the thalamic nuclei and the 
IC: structures which play an important part in pain regulation (Xu et al. 2003). 
The hypothalamus is another key structure involved in pain modulation and 
transmission. Its various nuclei have been strongly implicated in fear, emotional memory 
and behavior, and autonomic and somatomotor responses to threatening stimuli. 
Descending pathways extend from hypothalamus to the brain stem. Hypothalamic fibers, 
modulating afferent noxious stimuli, project to the thalamus, medulla oblongata (including 
nuclei of the trigeminal nerve), PAG and the substantia gelatinosa of the DH of the spinal 
cord (Sawchenko and Swanson 1982). 
The hippocampus, as another part of the limbic system, participates in important 
brain functions like learning and memory, attention and arousal, and is also involved in 
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stress- and pain-related behavioral responses. Analgesia produced by intrahippocampal 
lidocaine (injected into the dentate gyrus) provides evidence of the involvement of the 
hippocampal formation in pain perception (McKenna and Melzack 1992). Nociceptive 
information is processed in distributed fashion by the hippocampus, and at least the ventral 
CA1 is implicated in nociceptive intensity-dependent integrative functions (Khanna et al. 
2004). Two kinds of pain-related neurons were found here: pain-excited neurons (PEN) and 
pain-inhibited neurons (PIN). Experimental data suggest that muscarinerg acetylcholine 
receptors (mAchRs) play an important role in the modulation of nociceptive information in 
the hippocampal formation (Jiao et al. 2009, Yang et al. 2008). 
The involvement of the basal ganglia in motor functions has been well studied. 
Evidence from neuroanatomical, neurochemical, and electrophysiological studies suggests 
that the basal ganglia are also involved in nociception. The basal ganglia circuitry plays 
role in the sensory, affective and cognitive dimensions of pain, and may also be involved in 
the modulation and sensory gating of nociceptive information (Chudler and Dong 1995). 
Some patients with basal ganglia disease (e.g., Parkinson's disease, Huntington's disease) 
have alterations in pain sensation in addition to motor abnormalities. Frequently, these 
patients have intermittent pain that is difficult to localize. Rats with a unilateral nigrostriatal 
lesion show enhanced sensitivity to a wide range of painful stimuli, of both thermal and 
mechanical nature (Saade et al. 1997, Takeda et al. 2005); the opposite effect – decreased 
pain sensitivity – can be obtained by electrical stimulation of the substantia nigra pars 
compacta or by activating striatal dopaminergic receptors (Jurna et al. 1978, Lin et al. 1981, 
Sandberg and Segal 1978). 
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Endogenous antinociceptive ligands 
 
Pain is a dynamic phenomenon resulting from the activity of both excitatory and 
inhibitory endogenous modulation systems. It is well known that a multitude of substances 
and receptors are involved in the nociceptive system, some of them increase, and others 
inhibit the pain sensation both peripherally and centrally (Furst 1999, Sandkuhler 1996). 
Virtually no ligands/receptors are to be found that have not been investigated in this 
respect. These substances, which include neurotransmitters, neuromodulators, hormones, 
cytokines, etc., can modify the activity of nerves involved in the pain pathways. One of the 
physiological functions of the endogenous system is to tonically regulate nociceptive 
transmission; therefore the ratio of the pronociceptive and antinociceptive ligands 
determines the pain sensitivity. A very exciting and rapidly developing field of pain 
research relates to the roles of different endogenous ligands, acting on different receptor 
mechanisms. These substances have potentially advantageous features: their synthesizing 
and breakdown enzymes are available in the body; therefore, they have shorter half-lives 
and lower toxicity (Kristensen et al. 1993). On the other hand, certain endogenous ligands 
have lower specificity and affinity for their receptors compared with exogenous drugs, and 
they exert their effects at several types of receptors at different parts of the body (Fields et 
al. 1991). Therefore, the net effect depends on the localization of the ligands/receptors, and 
on which receptors and where they will be influenced by a ligand.  
 
Anandamide 
 
Both natural and synthetic cannabinoids (CBs) potently reduce pain-related behavior 
(Hohmann 2002, Pertwee 2001, Walker et al. 2002). Thus, CBs are highly effective against 
thermal, mechanical and chemical pain and are comparable to opiates in both potency and 
efficacy (Walker et al. 2002). A major limitation to the potential use of CB agonists as 
therapeutic agents is the profile of side effects, which include dysphoria, effects on motor 
coordination, memory, and abuse potential (Carlini 2004). An alternative approach, which 
may avoid such side effects, is to manipulate the endogenous CB system. The 
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endocannabinoid system consists of endogenous cannabinoids, cannabinoid receptors and 
the degrading enzymes responsible for synthesis and degradation of endocannabinoids. 
Soon after the identification of the CB receptors, it was discovered that the brain produces 
endogenous cannabinoids, which are capable of activating these receptors (Devane et al. 
1992).  
CB1 receptors are present in the central nervous system and also in some peripheral 
tissues including pituitary gland, immune cells, reproductive tissues, gastrointestinal 
tissues, sympathetic ganglia, heart, lung, urinary bladder and adrenal gland (Guindon and 
Hohmann 2007, Szabo 2008). Centrally the cerebral cortex, hippocampus, lateral caudate 
putamen, substantia nigra pars reticulata, globus pallidus, entopeduncular nucleus and the 
molecular layer of the cerebellum are all populated with particularly high concentrations of 
CB1 receptors, a distribution pattern that is consistent with the well-established ability of 
cannabinoids to alter locomotor activity and produce catalepsy, particularly in rodents, and 
to impair cognition and memory. Additionally, CB1 receptors are found on pain pathways 
in the brain and spinal cord and probably also at the peripheral terminals of primary 
afferent neurons and these receptors presumably mediate cannabinoid induced analgesia 
(Pertwee 2001). CB2 receptors, on the other hand, are expressed mainly by immune cells, 
particularly those derived from macrophages, such as B-cells, natural killer cells, microglia, 
osteoclasts and osteoblasts, but it has also been identified on neurons, under certain 
conditions particularly (Pertwee 1997). A common property of CB1 and CB2 receptors 
appears to be the ability to modulate spontaneous or evoked release of chemical 
messengers, generally to suppress neuronal excitability and inhibit neurotransmission. 
These actions seem to be signaled through the inhibitory Gi and Go proteins, negatively to 
adenylate cyclase and positively to mitogen-activated protein kinase, and also to various 
ion channels, (positively to A-type and inwardly rectifying potassium channels and 
negatively to N-type and P/Q type calcium channels and to D-type and postsynaptic M-type 
potassium channels) (Howlett et al. 2004, Pertwee 1997, Pertwee 2001). Additionally CB1 
receptors can also couple to Gs proteins to activate adenylate cyclase and/or to reduce 
outward potassium current, possibly through arachidonic acid-mediated stimulation of 
protein kinase C (Demuth and Molleman 2006). However evidences exist, that cannabinoid 
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receptor signaling and G-protein coupling efficiency is not the same in all brain areas 
(Devane et al. 1992). 
The endogenous cannabinoids are lipid derivatives and a feature that distinguishes 
them from many other neuromodulators is that they are not synthesized in advance and 
stored in vesicles. Rather, their precursors exist in cell membranes and are cleaved by 
specific enzymes on demand. Endocannabinoids are released generally postsynaptically, 
and act presynaptically (Walker et al. 2005). The first endocannabinoid identified was 
arachidonoyl-ethanolamine (anandamide: AEA), isolated from porcine brain and 
characterized as an endogenous eicosanoid with moderate affinity for the CB1 and CB2 
receptors (Devane et al. 1992). Several lines of evidence suggest that AEA also activates 
other G protein-coupled receptors (GPCRs) and ion channels. The best known and 
characterised of these ion channel interactions is the activation of the transient receptor 
potential vanilloid 1 (TRPV1) by AEA (Hajos et al. 2001, Olah et al. 2001, Oz 2006, 
Tognetto et al. 2001, van der Stelt et al. 2005, Zygmunt et al. 1999). TRPV1 is a ligand-
gated nonselective cation channel that is considered to be an important integrator of various 
pain stimuli such as capsaicin, heat and low pH (Jancsó et al. 1977, Jancsó and Lawson 
1987, Kau et al. 1991, Szekely et al. 1997, Yu et al. 2003). Since CBs and TRPV1 
receptors show co-expression in brain neurons, and AEA represents “chimeric” ligand 
acting on both cannabinoid and TRPV1 receptors, their co-activations can lead to a cross-
talk between them (Starowicz et al. 2008). Some of its effects, including antinociception, 
may be at least partially due to TRPV1 activation (Di Marzo et al. 2002, Jancsó et al. 1985, 
Jancsó and Király 1980, van der Stelt and Di Marzo 2004, Zygmunt et al. 1999). Previous 
results in our laboratory have shown that spinal AEA significantly decreased inflammatory 
thermal pain sensitivity, and its effects were modified by TRPV1 antagonist capsazepine 
(CAPZ), suggesting that the effective doses of AEA influence not only cannabinoid but 
also TRPV1 receptors (Horvath et al. 2008). 
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Endomorphin 
 
Since centuries, morphine has been the gold standard for the treatment of pain, 
against which all analgesics are compared. Due to several side effects and strong abuse 
potential, it has been desirable to find a similarly efficient but possibly safer way of 
antinociception. Early efforts to understand the endogenous targets of opiate drugs led to 
the identification of receptor sites. Binding studies suggested four main classes of opioid 
receptors, named µ-, -, - and opioid receptor-like receptors. Opioid receptors comprise a 
subfamily of structurally homologous GPCRs. Activation of these receptors inhibits the 
formation of cyclic adenosine 3',5'-monophosphate (cAMP), close voltage-gated Ca
2+
-
channels and opens inwardly rectifying potassium channels (Dhawan et al. 1996, Jordan et 
al. 2000, Lambert 2008). The net effect of these cellular actions is to reduce neuronal 
excitability and neurotransmitter release.  
 Opioid receptors and their endogenous ligands are widely distributed in the 
organism, thus the activation of this system might lead to effective antinociception (Akil et 
al. 1984, Bach 1997, Basbaum and Fields 1984, Bodnar and Klein 2004, Bodnar 2008, 
Horvath 2000, Menetrey and Basbaum 1987, Palkovits 2000, Pan et al. 2008, Rittner et al. 
2008, Vaccarino et al. 2000). The antinociceptive effects are produced by peripheral, spinal 
and supraspinal levels as well (Przewlocki et al. 1999). During inflammation of the 
peripheral tissues, numerous mediators are produced by endothelial cells, resident cells, and 
leucocytes that are recruited to the site of injury. Leukocytes are the important source of the 
endogenous opioid peptides, and in peripheral inflamed tissue -endorphin, Met-
enkephalin, dynorphins and endomorphins are produced and released by these cells (Labuz 
et al. 2006, Mousa et al. 2002, Rittner et al. 2008). Opioid receptors located within the 
superficial DH, in lamina I. and particularly in lamina II, and in the DRG of sensory 
neurons undergo axonal transport to reach peripheral nerve terminals, and inflammation 
induces increases in µ-opioid receptor binding within DRG leading to an improved 
antinociceptive potency in these circumstances (Endres-Becker et al. 2007, Mousa et al. 
2007, Zollner et al. 2003). Some of the analgesic actions of opioids may be due to 
modulation of the descending pathways (originating in RVM, PAG, LC, ACC, prefrontal 
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cortex and thalamic nuclei) to reduce nociceptive transmission in the DH (Anderson et al. 
1977, Basbaum and Fields 1984).  
Twelve years ago a novel group of specific μ-opioid receptor agonist tetrapeptides 
was discovered and named endomorphins (EMs). Endomorphin-1 (EM1) and 
endomorphin-2 have been isolated first from bovine and then from human brain cortex by 
Zadina et al. (Zadina et al. 1997). Compared to morphine, they possess partial, rather than 
full agonist properties at µ-opioid receptor sites, their effects are temporary and there is also 
an evidence suggesting a plateau effect, although the potencies of the drug and the duration 
of the
 
effects seemed to depend on the species, on the applied pain
 
tests, and on the route of 
administration (Horvath et al. 1999, Stone et al. 1997). Intraplantar administration of EM1 
dose-dependently decreased the mechanical allodynia and the thermal hypersensitivity in 
neuropathic and inflammatory pain models (Labuz et al. 2006, Obara et al. 2004). 
Intracerebrovascular or intrathalamic administration of EMs produced antinociception in 
both acute and chronic pain models (Zadina et al. 1997, Zhao et al. 2007, Zubrzycka et al. 
2005, Zubrzycka and Janecka 2008). Our previous results have demonstrated that 
intrathecal administration of EM1 is an effective method of inhibiting thermal hyperalgesia 
in rats (Csullog et al. 2001, Horvath et al. 1999). 
  
Adenosine 
 
Adenosine (ADE), originating from adenosine 5-triphosphate (ATP), is recognized to 
be an important modulator of neurotransmission in many physiological functions, such as 
regulation of arousal and sleep, anxiety, cognition and memory (Dunwiddie and Masino 
2001, Haas and Selbach 2000, Sawynok and Liu 2003). It is well known that the 
stimulation of its GPCR receptors (A1, A2A, A2B and A3) modifies pain signaling, and a 
variety of molecules have been developed to provide analgesia through this non-opioid 
mechanism (Poon and Sawynok 1998, Sawynok 1998). A1 receptors are present on the cell 
body of dorsal root ganglion cells and on the central terminals of primary afferent neurons 
(Macdonald et al. 1986, Santicioli et al. 1993). The action of A1 receptor agonists appears 
to be directly on the sensory nerve terminal itself and results from inhibition of adenylate 
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cyclase and a decreased production of cAMP (Fredholm et al. 1990, Khasar et al. 1995a). 
The role of the A1 adenosine receptor in inhibiting spinal sensory transmission has been 
confirmed by the inhibitory effect of A1 analogues on the C-fiber-evoked responses of 
wind-up and postdischarge of dorsal horn neurons, associated with nociceptive information 
(Reeve and Dickenson 1995). Actions due to adenosine A2 receptor activation have been 
proposed to result from stimulation of adenylate cyclase resulting in an increase in cAMP 
levels in the sensory nerve terminal (Khasar et al. 1995b, Taiwo and Levine 1991). The 
pronociceptive actions of A3 receptor activation are mediated by an effect on mast cells to 
release histamine and 5-hydroxytryptamine (5-HT), an action likely mediated by increased 
inositol 1,4,5-triphosphate (IP3) production and enhanced intracellular Ca
2+
 (Ramkumar et 
al. 1993, Sawynok et al. 1997). A study revealed that ADE directly inhibits the TRPV1 
channel in vitro, which might influence its antinociceptive potential (Puntambekar et al. 
2004).   
However ADE analogs cause a number of side-effects and therefore cannot be used 
for pain therapy, and ADE is only slightly effective in neuropathic and inflammatory pain 
states, without influencing the normal pain sensitivity (Chiari and Eisenach 1999, Kekesi et 
al. 2004a). 
 
Interactions of ligands in pain modulation 
 
Accordingly, their effectivity might be lower than that of synthetic drugs, 
suggesting that these ligands alone would not be ideal drugs for pain therapy. Therefore, a 
good possibility for overcoming these problems might well be a combination of different 
drugs (Horvath et al. 2001, Horvath and Kekesi 2006, Kekesi et al. 2002, Kekesi et al. 
2004a). Within the endogenous ligands, endomorphins, adenosine and anandamide have 
been investigated by several authors, but their interactions have not been characterized. 
The antinociceptive interactions of ADE receptor and CB agonists with opioids 
have been widely investigated (Lavand'homme and Eisenach 1999, Welch and Eads 1999). 
It is well known that synthetic and plant-originated CBs and opioids show synergistic 
antinociceptive interactions, however the interaction of the endogenous ligands acting at 
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these receptors were not investigated. Furthermore, only a small number of studies have 
been made of the interactions of ADE or AEA with drugs acting at other receptors or 
systems, and a few data are available concerning the effects of coactivation of the ADE and 
CB receptors (Begg et al. 2002, Dar 2000, Guindon et al. 2006, Horvath and Kekesi 2006, 
Kekesi et al. 2004b, Kekesi et al. 2004a, Murillo-Rodriguez et al. 2003, Welch and Eads 
1999). 
 
Pain sensation in schizophrenia 
 
Schizophrenia is one of the most severe and debilitating psychiatric disorders and a 
major public health problem. It is a devastating neuropsychiatric syndrome that
 
typically 
strikes in late adolescence or early adulthood resulting
 
in lifelong disability. Positive or 
psychotic symptoms, including
 
delusions and hallucinations, are the most apparent 
manifestation
 
of the disorder. These emerge episodically and usually trigger
 
the first 
hospitalization in early adulthood. Chronic aspects
 
of the disorder include negative 
symptoms such as social withdrawal,
 
flattened affect, and anhedonia as well as pervasive 
cognitive
 
deficits (Schmidt et al. 2008). The lifetime prevalence worldwide is between 0.5 
and 1%, accounting for around 20% of all persons treated
 
for mental illness and it appears 
to be relatively independent of geographic, cultural and socioeconomic variables.  
Clinical reports suggest that many patients with schizophrenia are less sensitive to 
pain than other individuals; this is associated with increased morbidity and mortality 
(Dworkin 1994, Jochum et al. 2006). The absence of pain report was confirmed by clinical 
studies of pain reactivity conducted in large samples of individuals with schizophrenia in 
different medically painful conditions such as acute perforated peptic ulcer, acute 
appendicitis, ruptured appendix, peritonitis, compartment syndrome, fractures or 
myocardial infraction (El Mallakh et al. 2005, Lautenbacher and Krieg 1994, Murthy et al. 
2004, Rosenthal et al. 1990, Singh et al. 2006, Torrey 1979). Clinically, diminished pain 
sensitivity in schizophrenia has been linked to key symptoms of the disorder, such as 
positive symptoms, active flattening, and/or attention deficits. On neurobiological grounds, 
disturbances in dopamine, serotonin, glutamate and opioids have been proposed to account 
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for hypoalgesia in schizophrenia. Some authors suggest that it can be related to abnormal 
excitatory mechanisms, a different mode of pain expression due to cognitive impairments 
and disturbances of body schema, a decrease in social communication or, as described in 
most cases, any observed increase in pain perception threshold was the result of “attitude”, 
but not alteration in brain function (Kuritzky et al. 1999). Thus, the current state of science 
does not provide an unequivocal description of diminished pain sensitivity in schizophrenia 
therefore, a satisfactory explanation for hypoalgesia in schizophrenia is lacking (Potvin et 
al.).  
There are several tests to examine pain perception in schizophrenia. Most of these 
are mainly based on a psychophysical method (self measurement of pain perception using a 
scale) or a method using the signal detection theory (the pain response is measured by the 
individual‟s ability to discriminate the sensory stimuli and by response criteria reflecting 
their attitude after painful stimuli). One experimental study deserves special attention 
because it has used a neurophysiologic measure of pain reactivity, the nociceptive RIII 
reflex threshold. The RIII reflex is studied by applying percutaneous electrical stimulation 
on the sural nerve and recording the reflex motor response from the biceps femoris muscle 
(a flexor muscle). Studies conducted on healthy participants have shown that the amplitude 
of the RIII reflex is correlated proportionally with the participant‟s self-reported pain 
threshold (Guieu et al. 1994). 
However to investigate the pathophysiology and the possible medication of 
schizophrenia over the years, several effort have been made to generate a possible animal 
model that could mimic this human disease. There are three main methodical procedures 
applied mainly on rodents: neurodevelopmental, neurochemical and genetic models.  
Encompassing the neurodevelopmental hypothesis of schizophrenia, manipulation 
of the environment, triggering chronic stress, can modify young animals‟ nervous system 
and therefore produce schizophrenia like alterations. As rats represent a social species, 
interaction with other rats is essential to ensure a normal neurological and physiological 
maturation; therefore, isolation causes behavioral changes, including decreased pain 
sensitivity, increased spontaneous locomotor activity, deficits in learning and memory, and 
increased aggression to altered reactivity to external stimuli (Gentsch et al. 1988, Paulus et 
al. 2000, Varty et al. 2006, Weiss and Feldon 2001). Social isolation of animals results in 
 27 
altered neurochemical systems such as enhanced presynaptic dopaminergic function in the 
nucleus accumbens and the prefrontal cortex, a decrease in presynaptic serotonergic 
function, and an imbalance in dopamine and 5-HT in the frontal cortex (Crespi et al. 1992, 
Fone et al. 1996, Jones et al. 1992). These behavioral and neurochemical changes have 
been suggested to be similar to the changes seen in patients with schizophrenia, thus the 
postweaning isolation housing paradigm may provide a nonpharmacological 
neurodevelopmental method of inducing schizophrenia-like behavioral deficits and has 
potential utility in the screening of novel antipsychotic drugs (Geyer et al. 1993, 
Muchimapura et al. 2003, Paulus et al. 2000, Roberts and Greene 2003, Varty et al. 1999). 
Neurochemical substances applied systemically or locally over different regions of 
the CNS are often used, either to create a psychotic state, or to study the role of different 
nuclei of the brain, through their degeneration, in the pathophysiology of schizophrenia 
respectively. The same neurodegenerative effect can be targeted when surgically destroying 
the corresponding areas of the brain. There is mounting evidence that the glutamate 
neurotransmitter system, and in particular N-methyl-D-aspartic acid (NMDA) receptor 
hypofunction, might be a contributing factor leading to symptoms of this illness (Brenner et 
al. 2007, Kristiansen et al. 2007, Muller and Schwarz 2006, Stone et al. 2007). NMDA 
receptor expression and localization is disrupted in patients with schizophrenia, and 
exposing rodents to NMDA receptor antagonists causes certain schizophrenia-like 
behaviors (Becker and Grecksch 2004, Guo et al. 2009, Kristiansen et al. 2007).  
Lately different genetic models have been used to study the pathophysiology of 
schizophrenia mainly on knock-out mice lacking enzimes or regulating proteins like 
dopamine transporter, neuregulin1, reelin or NR1 subunit of the NMDA receptor, etc. 
(Tuboly and Horvath 2009). Although these models are promising, some of them cause 
changes not found in humans, and they usually can not reproduce all of the sypmtoms of 
the disease by themselves. Therefore the combination of the above mentioned different 
methods might be a more reasonable concept. 
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Aim of the studies 
 
Earlier studies proved that EM1, AEA and ADE can produce antinociceptive effects 
at spinal level. The goal of the first part of the thesis was to determine the interactions of 
AEA with EM1 and ADE in an inflammatory thermal pain model at spinal level. We also 
investigated the effects of the ADE receptor antagonist caffeine (CAFF) on the 
antinociceptive potency of AEA and ADE. Therefore, the main objectives of the first part 
of the Thesis were: 
 
1. To determine the dose–response and time course of intrathecally administered AEA and 
EM1.  
2. To characterize the interaction of EM1 and AEA. 
3. To test the antinociceptive interaction of ADE and/or CAFF with AEA. 
 
A recent study has shown that subchronic ketamine treatment and subsequent social 
isolation produces changes in pain sensitivity in adult rats (Becker et al. 2006). These data 
suggest that these manipulations in adult animals cause only slight changes in pain 
threshold, and the changes are mainly due to the isolation. Since postweaning social 
isolation is a more striking stress for juvenile animals, we supposed that combination of 
experimental approaches, that is, social isolation and treatment with the noncompetitive 
NMDA receptor antagonist ketamine in young animals might produce an animal model that 
bears more resemblance to the disease state of patients suffering from schizophrenia, at 
least in terms of pain sensitivity.  
As described above, the nociceptive pathway is now understood to be a dual system 
at each level, and the sensation of pain is considered to arrive in the CNS with the 
discriminative component of pain (“first pain”) carried separately by myelinated A -fibers 
from the effective-motivational component of pain (“second pain”) by unmyelinated C-
fibers. Rapid heating of the skin preferentially activates A -nociceptors, whereas a slower 
rate of heating preferentially activates C-fiber nociceptors (Yeomans et al. 1996, Zachariou 
et al. 1997). 
Therefore, the goals of the second part of the Thesis were: 
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4. To characterize the effects of postweaning ketamine treatment, postweaning social 
isolation, and the combination of these treatments on acute heat pain sensitivity at low and 
high temperature. 
5. To determine the effect of these manipulations on heat hyperalgesia and 
6. To investigate the antihyperalgesic potency of morphine in carrageenan-induced 
inflammatory model. 
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Methods 
Intrathecal catheterization 
 
The procedures involved in animal surgery and testing were approved by the 
Institutional Animal Care Committee of the University of Szeged, Faculty of Medicine. 
Adult, male Wistar rats (224 ± 1.9 g) were anesthetized with a mixture of ketamine 
hydrochloride and xylazine (72 and 8 mg/kg intraperitoneally: i.p., respectively). An 
intrathecal catheter (PE-10 tubing) was inserted through the cisterna magna and passed 8.5 
cm caudally into the subarachnoid space (Yaksh and Rudy 1976), which served to place the 
catheter tip between Th12 and L2 vertebrae, corresponding to the spinal segments that 
innervate the hindpaws (Dobos et al. 2003). After surgery, the rats were housed 
individually, and they had free access to food and water. Rats exhibiting postoperative 
neurologic deficits (about 10%) or those that did not show paralysis of one of the hindpaws 
after 100 µg lidocaine were excluded (Dobos et al. 2003). The rats were allowed to recover 
for at least four days before the testing and were assigned randomly to the treatment groups 
(6–15 rats/group).  
 
Social Isolation and Ketamine Treatment 
 
In the 2
nd
 part of our work, after weaning (on day 21–23 of age: 1st day) male 
Wistar rats were either housed individually or grouped for 21 days in cages measuring 42 × 
15 × 12 cm and 42 × 30 × 12 cm, respectively (l × w × h). The animals were treated daily 
from day 7 to day 20 with either ketamine (30 mg/kg) or saline intraperitoneally. In total, 
the rats received 14 injections. Duration of treatment was adapted from the study by Becker 
et al. (Becker et al. 2006). Four experimental groups were studied (n=9–11 
rats/housing/treatment condition): saline + non-isolated (sal-niso), ketamine + non-isolated 
(ket-niso), saline + isolated (sal-iso), and ketamine + isolated (ket-iso). Groups were 
matched according to body weight (55 ± 0.6 g). Rats were kept in a temperature controlled 
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room (22  1 ºC); food and water were available ad libitum. The cages were located 
together in racks so that auditory and olfactory contact was maintained. 
The test schedule of the experimental paradigm is presented in Fig.1. A total of 
three tail-flick test series were performed after the treatment period. The first one was 
performed 24 h after the last injection, and then all rats were rehoused in groups of 4–6 
with similar housing and treatment conditions and remained housed for the next 5 weeks. 
Two and four weeks later, tail-flick tests were repeated. By this time, ketamine was 
expected to have been cleared since ketamine administered by i.p. injection has been 
reported to have a terminal half-time of 5.4–5 h and does not significantly accumulate in 
the brain (Hijazi et al. 2003). Paw withdrawal test was carried out on the 5th week. The 
body weights of all experimental groups were measured throughout the investigation 
period. 
 
 
Figure 1. Experimental paradigm for schizophrenia model. TF: tail-flick, PWD: paw-withdrawal test.  
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Drugs 
 
The following drugs were used: ketamine hydrochloride (Calypsol, Richter Gedeon 
RT, Budapest, Hungary) morphine hydrochloride (Hungaropharma, Budapest, Hungary), 
and xylazine hydrochloride (Rompun, Bayer, Leverkusen, Germany). ADE, CAFF, EM1 
and AEA were purchased from Sigma-Aldrich (Budapest, Hungary). AEA (MW: 348 kDa) 
was dissolved in ethanol: Tween = 2:1, CAFF in ethanol, ADE and EM1 (MW: 610.7 kDa) 
in saline. Stock solution of AEA and CAFF was diluted with saline to a final concentration 
of 10% (20 µM) ethanol (and 5% Tween in the AEA solution). Intrathecally administered 
drugs were injected over 120 s in a volume of 10 µl, followed by a 10 µl flush of 
physiological saline, and vehicle (Veh) -treated animals formed the control group. In the 
schizophrenia model experiment physiological saline served as a control against ketamine 
treatment, and freshly prepared solutions were injected i.p. at a volume of 4 ml/100 g body 
weight. 
Nociceptive testing 
 
The paw-withdrawal test (PWD) was used to measure the antinociceptive effects of 
the applied substances on carrageenan-induced inflammation (Hargreaves et al. 1988). Rats 
were placed on a glass surface in a plastic chamber and were allowed to acclimatize to their 
environment for 15–30 min before testing. The baseline hindpaw withdrawal latencies (pre-
carrageenan baseline values at 180 min) were then obtained. A heat stimulus was directed 
onto the plantar surface of each hindpaw and the intensity of the thermal stimulus was 
adjusted to derive an average baseline latency of approximately 10.0 s. The cut-off time 
was set at 20 s to avoid tissue damage.  
Unilateral inflammation was induced by intraplantar injection of 2 mg carrageenan 
in 0.1 ml physiological saline into one of the hindpaws (on the paralyzed side during the 
lidocaine test; see above (Dobos et al. 2003)). This induced hyperalgesia peaking at 3-4 h 
after the injection. PWD latencies were obtained again 3 h after carrageenan injection (post-
carrageenan baseline values at 0 min). In the case of the first part of the study, AEA, EM1, 
or their combinations (for the doses applied and the number of animals see Table 2) were 
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injected after the determination of the post-carrageenan baseline value. PWD latencies were 
registered 5 min after the injection, and then every 10 min up to 70 min. As regards the 
experiments with AEA and drugs acting on ADE receptors, 400 µg CAFF or its Veh was 
injected after determination of the post-carrageenan baseline value (-20 min), the second 
injection (100 µg ADE or its Veh) 10 min later (-10 min), and the third one (100 µg AEA 
or its Veh) at 0 min. Since our earlier study showed low potency of ADE, we applied 
pretreatment with a single high dose of ADE (100 µg) (Kekesi et al. 2004a, Kekesi et al. 
2004b). The dose of CAFF administered (400 µg) was based on an earlier study (Esser and 
Sawynok 2000). The paw withdrawal latencies were registered twice between the injections 
(at -15 and – 5 min), at 5 min after the third injection, and then every 10 min until 70 min. 
In the second part of the study, the antihyperalgesic potency of morphine (1, 2, and 3 mg/kg 
subcutaneously) was determined in the same model for 120 min. 
Acute nociceptive threshold was assessed by the tail-flick test. The reaction time in 
the tail-flick test was determined by immersing the lower 5 cm portion of the tail in hot 
water (48 and 52 °C) until a tail-withdrawal response was observed (cut-off time: 20 s). 
The tail-flick latencies were obtained three times (at both temperatures consecutively) at 0, 
30, and 60 min and, since they did not differ significantly, they were averaged to establish 
the pain threshold for each group at both temperatures. There was a 30 min resting period 
between the measurements. We started the experiments at 48 
o
C then proceeded at 52 
o
C. 
 
Endomorphin-1 (µg) 
 0 0.01 0.1 1 10 
Anandamide (µg)      
0 11 8 10 11 10 
1.5 8 9 9 10 9 
10 12 8 8 8 7 
30 10 9 8 11 10 
100 7     
Table 2.   Experimental paradigm, showing the doses of EM1 and AEA, and the number of animals used in 
each group.  
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Statistical analysis 
 
Data are presented as means ± SEM. As regards the first series of experiments 
(interaction of EM and AEA), treatments generally resulted in a short-lasting effect, with 
the peak occurring at 5–10 min, therefore, their mean values (5 and 10 min) at the inflamed 
side were used for dose–effect curves and the linear regression analysis. For this analysis 
PWD latencies were transformed to % maximum possible effect (%MPE) by using the 
following formula: 
%MPE = ( observed latency – post-carrageenan baseline latency / cut off time – post-
carrageenan baseline latency ) × 100 
Dose–effect curves were constructed for both drugs and their combinations. The 35% 
effective dose (ED35) was defined as the dose that yielded 35% MPE, which means perfect 
antihyperalgesic effect. Because a higher level of the effect might also be important for 
therapeutic practice, we also determined ED60 for EM1 and the combination with AEA. 
The ED35 and ED60 values with 95% confidence intervals (CI) were calculated by linear 
regression.  
Data sets were examined by one-way and two-way analyses of variance and repeated 
measures ANOVA, while the results of social isolation/ketamine treatment were analyzed 
using three-way ANOVA (factors: housing, treatment, and time with repeated 
measurements). The significance of differences between experimental and control values 
was calculated using the Fisher LSD test for post hoc comparison. A P value less than 0.05 
was considered significant. Data were analyzed using STATISTICA 7.1. (Statsoft Inc., 
Tulsa, OK) and GraphPad Prism (GraphPad software Inc. La Jolla, California, USA) 
softwares.  
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Results 
 
Antinociceptive potency of endogenous ligands by themselves 
 
Basal thermal withdrawal latency was 9.1  0.08 s. Carrageenan caused a 
significant decrease in PWD latency at the inflamed side (3.1  0.08 s), while it did not 
significantly influence that at the noninflamed side. Because administration of Veh caused 
a slight decrease in the hyperalgesia, the treated groups were compared to the vehicle-
treated one. Anandamide caused dose-dependent antihyperalgesia (Fig. 2.). The ED35 value 
was 67.65 µg (CI: 44.92–90.37), therefore we could not calculate with ED60 value. In terms 
of its time course, the lowest dose was ineffective, but both 30 and 100 µg AEA caused 
prolonged antihyperalgesic effect through the whole investigated period. However, it 
should be mentioned that 100 µg AEA also caused temporary vocalization and excitation, 
suggesting a pain-inducing potential of AEA; therefore, the highest dose of AEA in the 
combination was 30 µg. 
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Figure 2. Time course of the effects of AEA on the noninflamed (left) and inflamed (right) sides. The arrows 
show the injections. Each point denotes the mean  SEM of the results. * indicates a significant (p < 0.05) 
difference as compared with the vehicle-treated group.  
 
Endomorphin-1 alone caused dose-dependent antinociception at both inflamed and 
noninflamed sides, that is, 0.01 µg EM1 was ineffective, while 10 µg caused not only a 
perfect relieve of hyperalgesia, but also a significant antinociception at both sides (Fig. 3.). 
Regarding the time-course effect of EM1, only 10 µg produced long-lasting 
antihyperalgesia, whereas its antinociceptive effect was short-lived (5–20 min). The ED35 
and ED60 values were 1.95 µg (CI: 0.6–3.3) and 6.95 µg (CI: 4–8.4), respectively, therefore, 
its potency was higher compared with AEA. 
As regards the effects of ADE (100 µg) and CAFF (400 µg) alone, the comparisons 
with the control group by two-way ANOVA did not reveal significant differences by 
treatments (Fig. 4).  
 
 
Figure 3. Time course of the effects of EM on the noninflamed (left) and inflamed (right) sides. The arrows 
show the injections. Each point denotes the mean  SEM of the results. * indicates a significant (p < 0.05) 
difference as compared with the vehicle-treated group.  
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Figure 4. Time course of the effects of ADE (100 µg), CAFF (400 µg) and their combination on the thermal 
hyperalgesia. The 1
st
, 2
nd
 and 3
rd
 arrows show the injection of CAFF/vehicle, ADE/vehicle and AEA/vehicle, 
respectively. The symbol * denotes a significant (p<0.05) difference as compared with the vehicle-treated 
group. The symbol x indicates a non-significant difference between the data point and the pre-carrageenan 
baseline value.  
 
Interaction of Anandamide and Endomorphin-1 
 
Regarding the interaction of these ligands, the effect of EM1 was not influenced by 
AEA at the noninflamed side; therefore results were analyzed only at the inflamed paws. 
1.5 µg AEA did not change the effects of EM1 in any doses, which is in accordance to its 
low efficacy (data not shown). The effect of 0.01 µg EM1 was increased by 10 and 30 µg 
AEA, and the combination of 0.1 µg EM1 and 30 µg AEA was more effective, than by 
themselves at 5 and 10 min after the administration of the drugs (Figs. 5., 6., 7.). Further 
combinations (Table 2.) were not more effective than EM1 by itself (data are not shown).  
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Figure 5. Time course of the antinociceptive effects of 0.01 μg EM in combination with 10 μg AEA. Each 
point denotes the mean  SEM. * indicates a significant (p < 0.05) difference compared to the EM-treated 
group. # denotes a significant difference compared to the AEA-treated treated groups. 
 
 
Figure 6. The antinociceptive effects of 0.01 μg EM in combination with 30 μg AEA. Each point denotes the 
mean  SEM. * indicates a significant (p < 0.05) difference compared to the EM-treated group. # denotes a 
significant difference compared to the AEA-treated treated groups. 
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Figure 7. Time course of the antinociceptive effects of 0.1 μg EM with 30 μg AEA. Each point denotes the 
mean  SEM. * indicates a significant (p < 0.05) difference compared to the EM-treated group. # denotes a 
significant difference compared to the AEA-treated treated groups. 
 
As the ratio of the ED35 values of EM1/AEA was 33.82, the doses of the 
combinations were calculated in this proportion (Tallarida et al. 1989). The dose–response 
curves revealed that the slopes of the dose–response curves for EM1 and cocktail did not 
differ significantly (Fig. 8.). Similarly, the ED35 and ED60 values of the combination [1.35 
(CI: 0.4–2.3) vs. 7.6 (CI: 6.1–9.1) µg] also did not differ markedly from the EM1-treated 
groups suggesting additive interaction between these ligands. 
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Figure 8.  The magnitude of the dose-dependent effects of EM and AEA alone and their combinations.  
 
Interaction of Anandamide with Drugs Acting on Adenosine Receptors 
 
The CAFF and ADE cotreatment caused a significant increase in the paw withdrawal 
latency relative to the control group, and the post-hoc analysis revealed significant 
differences at -5 and 5 min, suggesting a short-lasting effect of this combination (Fig. 4). 
Pretreatment with ADE (100 µg) or CAFF (400 µg) did not change the effect of AEA in 
lower doses (1 and 33 µg) (data not shown). However, the antihyperalgesic potential of 100 
µg AEA was decreased both by ADE and by CAFF (Figs. 9. and 10.). The time-response 
curve demonstrated that the triple combination of 100 µg AEA + ADE + CAFF was more 
effective than the combination of CAFF + ADE + Veh between 5 and 50 min, but 
comparison with the AEA-treated group showed a significant difference only 5 min after 
the last injection (Fig. 9.).  
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Figures 9., 10. Time course of the effects of double and triple combinations containing AEA. The 1
st
, 2
nd
 and 
3
rd
 arrows show the injection of CAFF/vehicle, ADE/vehicle and AEA/vehicle, respectively. The symbol * 
denotes a significant (p<0.05) difference from the correspondence group without AEA. #: significant 
difference as compared with the AEA treatment group by itself. 
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Social Isolation and Ketamine Treatment 
 
Tail-flick test 
 
As regards the tail-flick latencies at 48 °C, three-way ANOVA revealed a significant 
effect of housing (F1,38 = 17.39, p< 0.001) and time (F2,74= 25.01; p<0.001) conditions on 
pain sensitivity, but ketamine treatment did not influence it. Juvenile isolation resulted in 
lengthened tail-flick latency when compared with nonisolated rats throughout the 
investigation period (Fig. 11). However, the difference between the groups decreased on the 
35
th
 day; therefore, there were no significant differences between the four groups. In contrast, 
tail-flick latencies in both isolated groups differed significantly from niso-sal group four 
weeks later, but not from the niso-ket animals, because the latency in this group moderately 
increased. In addition, tail-flick latency was significantly longer on the 42
nd
 day when 
compared with 21
st
 and 35
th
 days in all groups, but there were no significant differences 
between the values observed on the 21
st
 and 35
th
 days. 
The tail-flick latency at 52 °C was significantly shorter when compared with 48 °C 
at each time point. Three-way ANOVA revealed a significant effect of time (F2,74=104.50, 
p<0.0001) and there was a trend toward significance in the effect of housing conditions 
(p=0.058) (Fig. 11). In all groups, the tail-flick latency was significantly longer on the 35
th
 
and 42
nd
 day when compared with that on the 21
st
 day, but there was no significant 
difference between data registered on the 35
th
 and 42
nd
 days. Thus the pattern of changes in 
tail-flick latencies differed at 48 °C and 52 °C (Figs. 11, 12). 
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Figure 11. The tail-flick latencies at 48 °C immediately, 2 and 4 weeks after cessation of social isolation 
and/or ketamine treatment. Each point denotes the mean  SEM of the results on 9–11 animals. Symbol * 
indicates a significant (p<0.05) difference between groups. Symbol # indicates a significant difference from 
the tail-flick latency determined on the 21st day. 
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Figure 12. The tail-flick latencies at 52 °C immediately, 2 and 4 weeks after cessation of social isolation 
and/or ketamine treatment. Each point denotes the mean  SEM of the results on 9–11 animals. 
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PWD test 
 
The pre-carrageenan baseline latencies did not indicate significant difference 
between the groups, but there was a trend toward significance in the effect of housing 
conditions after the administration of carrageenan on the inflamed side (p=0.14). On either 
side, 1 mg/kg morphine was ineffective in the groups, while both 2 and 3 mg/kg morphine 
caused significant increases in PWD latency at several time points (Figs. 13 and 14).  
2 mg/kg morphine produced antihyperalgesic effect in all groups except the niso-sal 
treated animals. As regards the effects of this dose on the non-inflamed side, it caused 
significant antinociception in each group. The highest dose of morphine produced 
antinociception and antihyperalgesia in all groups, and there were no significant differences 
between the groups. 
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Figure 13. Time-course of the antinociceptive effects of morphine (1, 2 and 3 mg/kg) at inflamed sides on 
paw-withdrawal test. The first arrow shows the injection of carrageenan, the second one the administration of 
morphine. Each point denotes the mean  SEM of the results in 6–8 animals. The group-symbols indicate a 
significant (p<0.05) difference compared to the post-carrageenan baseline value. 
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Figure 14. Time-course of the antinociceptive effects of morphine (1, 2 and 3 mg/kg) at non-inflamed sides 
on paw-withdrawal test. The first arrow shows the injection of carrageenan, the second one the administration 
of morphine. Each point denotes the mean  SEM of the results in 6–8 animals. The group-symbols indicate a 
significant (p<0.05) difference compared to the post-carrageenan baseline value. 
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Discussion 
 
Antinociceptive potency of drugs at spinal level 
 
The results of the first part of my Thesis show that spinal AEA and EM1 dose-
dependently decreased inflammatory thermal pain sensitivity by themselves, and EM1 has 
much higher potency. ADE and CAFF alone did not induce antinociception. The 
coadministration of AEA and EM1 in different combinations revealed that only one 
cocktail showed potentiated antihyperalgesia. The effects of AEA were moderately 
influenced by ADE, CAFF and their combinations.  
As regards the action mechanism of AEA, it may produce antinociception through 
the activation of CB1 and CB2 receptors (Ahluwalia et al. 2000, Hohmann et al. 1999, 
Yaksh et al. 2006). Some data have shown that the CB1 antagonists have blocked the 
antinociceptive effects of AEA, while others indicated only partial antagonism, or even no 
inhibition at all (Di Marzo et al. 2000, Harris et al. 2001, Yaksh et al. 2006, Welch et al. 
1998). Since microglial activation is also associated with pain and CB2 receptors can 
depress immune cell activation at spinal level, it cannot be excluded that the administration 
of AEA also has anti-inflammatory potency, and this may contribute to its antinociceptive 
effects (Pertwee 2005, Romero-Sandoval and Eisenach 2007). Di Marzo et al. suggested for 
the first time that AEA at the spinal level does not produce analgesia only through CB 
receptor activation (Di Marzo et al. 2000). As AEA activates TRPV1 receptors too, its role 
in the effects of AEA should be considered (Zygmunt et al. 1999). Thus, it was observed 
that AEA at the highest dose caused temporary painful behavior, also suggesting activation 
of the TRPV1 receptors, which integrate multiple pain stimuli (Hayes and Tyers 1980, 
Jancso and Jancso-Gabor 1980). The activation of TRPV1 receptors by capsaicin not only 
induces the excitation of nociceptors and the release of pain-inducing transmitters, but also 
causes the release of endogenous antinociceptive ligands, such as beta-endorphin or 
somatostatin (Bach and Yaksh 1995b, Jancsó et al. 1985, Jancsó and Lawson 1990, 
Szolcsányi et al. 1998a). Some data suggest that TRPV1, but not CB1 receptors, are 
involved in AEA induced responses in the dorsal root primary neurons in vitro, and it has 
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been suggested that the analgesic properties of AEA are likely to be mediated, at least to 
some extent, by TRPV1 activation in vivo (Ahluwalia et al. 2003, Horvath et al. 2008, 
Jerman et al. 2002). It has been shown that low dose of capsaicin (0.25 µg intrathecally) 
induced painful behavior during the injection (similarly to AEA), but it caused short-lasting 
analgesia (5-15 min), which was decreased by CAPZ (Horvath et al. 2008). Furthermore, 
Del Carmen Garcia et al. have reported that CAPZ blocked the hypotensive effect of AEA 
(17–35 µg), demonstrating the in vivo role of TRPV1 activation in the effect of AEA at 
spinal level (del Carmen Garcia et al. 2003). It may be hypothesized that through the 
activation of CB1 receptors, AEA at low concentration decreased the transmitter release, 
while in higher doses it increased the transmitter release via the TRPV1 receptors 
(Ahluwalia et al. 2003). We presume that the acute activation of primary sensory neurons 
by high dose of AEA (100 µg) might have caused the short-lasting painful behavior, while 
the antinociceptive potential of TRPV1 receptor activation might be due to the release of 
endogenous antinociceptive ligands at spinal level (Bach and Yaksh 1995a, Szolcsányi et 
al. 1998a, Szolcsányi et al. 1998b). An additional problem is that AEA acts as a 
noncompetitive inhibitor of serotonine-3 and nicotinic acetycholine receptors, directly 
inhibits the voltage-sensitive Na
+
 channels and influences the glycine channels (Hejazi et 
al. 2006, Kim et al. 2005, Lozovaya et al. 2005, Oz et al. 2002, Oz 2006). Moreover, it is 
likely that other GPCRs are also involved in some of the actions of AEA observed in CB-
receptor knockout mice (Hajos et al. 2001, Oz 2006). In summary, several systems may be 
influenced by AEA, and their net effect may be observed under these circumstances.  
Similarly to earlier results, the administration of EM1 elicited dose-dependent 
antinociception with high potency (Csullog et al. 2001, Horvath et al. 1999, Horvath 2000, 
Tseng et al. 2000, Yu et al. 2004, Zadina et al. 1997). Some data suggested that EMs 
displayed lower potencies in the mechanical (paw pressure) test than in the heat-pain (TF) 
test in rats after intrathecal administration, but they exerted high analgesic potency in 
different inflammatory pain models as well (Csullog et al. 2001, Hao et al. 2000, Horvath et 
al. 1999, Horvath et al. 2007b, Labuz et al. 2003, Przewlocka et al. 1999, Wang et al. 
1999). Since neuropathic pain has been assumed to be resistant to treatment with opioids, it 
is of particular interest that the EMs have high potency in decreasing neuropathic pain 
(Przewlocka et al. 1999). EM1, but not EM2, dose-relatedly reduced the A -fiber evoked 
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responses, therefore, spinal EM2 exerts selective effects on noxious responses, whereas 
EM1 is non-selective (Chapman et al. 1997). These ligands by activation of µ-opioid 
receptors on primary sensory, interneurons and projecting neurons in the spinal cord inhibit 
the transmission of pain stimuli after its intrathecal administration.  
The low potency of ADE is consistent with earlier results which indicated that ADE 
was almost ineffective in different pain models, while data on the antinociceptive potential 
of CAFF are controversial and the overall evidence from clinical studies is weak (Camann 
et al. 1990, Diener et al. 2005, Chiari et al. 1999, Kekesi et al. 2004b, Kekesi et al. 2004a, 
Lavand'homme and Eisenach 1999). Animal studies have suggested that CAFF induces 
antinociception, but could inhibit the antinociceptive potential of ADE analogs (Sawynok 
and Reid 1996, Sosnowski and Yaksh 1989). Surprisingly, the coadministration of ADE 
and CAFF led to a short-lasting antihyperalgesic effect, suggesting some kind of 
potentiation between them. At first sight this is controversial, however, their interaction 
might have been complicated by the fact that they influence all types of ADE receptors 
with different affinities to the receptor subtypes, and studies have demonstrated opposing 
roles for the receptor subtypes (Patel et al. 2001, Quarta et al. 2004). Furthermore, ADE 
receptor activation decreases not only the excitatory, but also the inhibitory transmitter 
release at spinal level, which could mask its antinociceptive potential (Yang et al. 2004). 
The A1 receptor has been proposed to exist as a part of a µ opioid and α2–adrenergic 
multireceptor complex on the basis of a demonstrated cross antagonism, cross tolerance and 
cross withdrawal between these systems (Aley et al. 1995).  Stimulation of ADE receptors 
also inhibits the inflammation, therefore, this may contribute to its antinociceptive effect 
(Cronstein, 1994). Additionally, the mechanism of action of ADE may be complicated by 
its interaction with the TRPV1 receptors (Puntambekar et al. 2004). It has been shown that 
ADE and ADE analogs directly inhibit capsaicin-mediated TRPV1 activation, supporting a 
role of this nucleoside as an endogenous modulator of TRPV1. In contrast, the activation of 
TRPV1 in the spinal cord and the periphery promotes the increased release of ADE, 
possibly through increased intracellular Ca
2+
 entry through the TRPV1 (Cahill et al. 1993). 
CAFF also has several effects on other (nonadenosine receptor-related) systems which 
might be connected with pain mechanisms. Thus, it inhibits phosphodiesterases, leading to 
elevated levels of cAMP and cGMP, and it can also mobilize intracellular Ca
2+ 
stores by 
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activation of the ryanodine receptors (Mandel 2002, Sawynok 1998). All of these effects 
could influence the pain sensitivity even in opposite ways (Yoon et al. 2006). Accordingly, 
although we expected antagonism between ADE and CAFF, it may be speculated that the 
potentiation observed here might be due to the concurrent influence of the above-mentioned 
receptors/systems. The mechanism of the studied interactions should be very complex, as 
these ligands may affect multiple receptors pre- and/or postsynaptically in the spinal cord 
(Table 3.) (Hohmann et al. 1999, Schulte et al. 2003, Schulte and Fredhohn 2003, Szallasi 
et al. 1995). 
 
Ligand AEA ADE CAFF 
G-protein related 
CB1/CB2    
Other GPCRs    
A1    
A2a    
A2b    
A3    
Ion-channel 
Glycine-R    
Ryanodine-R    
NAch-R    
VGNa
+
    
5-HT3-R    
TRPV1-R    
Enzyme 
phosphodiesterase    
 
Table 3. Action mechanisms of the ligands. , : activation or inhibition by the ligand, respectively. CB1/CB2: 
cannabinoid receptor 1, 2 respectively, A: adenosine, 5-HT3-R: serotonin-3 receptor; Nach-R: nicotinic achetylcholine 
receptor, VGNa+: voltage-gated Na+ channel  
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It is well known that exogenous opioids and cannabinoids produce synergistic 
antinociceptive interaction, although in the case of the endogenous ligands only one 
combination was more effective than the endogenous ligands by themselves. The possible 
cause of this difference might be the fact that EM1 exerts effects by µ-opioid receptors, 
while AEA has much more complex effect, as discussed above. We have found that neither 
ADE nor CAFF potentiated the antinociceptive effect of AEA at spinal level in these pain 
models, and even some kind of antagonism could be found. Further, the coadministration of 
ADE and CAFF moderately modifies the antinociceptive potential of AEA. A1 receptor is 
known to be localized on the same terminals as the CB1 receptors and utilizes the same 
signal transduction cascade as the CB1 receptors (Ahluwalia et al. 2000, Coggeshall and 
Carlton 1997). Since AEA and ADE exert opposite effects on the TRPV1 receptors in vitro, 
we initially expected that the action of AEA on TRPV1 receptors would be inhibited by 
ADE. We presumed that after blockade of the ADE receptors (by CAFF), ADE would act 
mainly as a TRPV1 antagonist, and the triple combination of these drugs would therefore 
antagonize the effect of AEA on the TRPV1 receptors. Our earlier result that CAPZ 
decreased the antinociceptive potential of AEA led us to expect similar results (Horvath et 
al. 2007a). However, the triple combination did not change significantly the effectivity of 
AEA, which might be due to their multifaceted interactions. As µ-opioid, cannabinoid CB1, 
adenosine and TRPV1 receptors are expressed in the dorsal horn of the spinal cord, and 
because they are coexpressed, at least partially on primary sensory neurons, EM1, ADE and 
AEA could all regulate the release of transmitters from the sensory neurons by acting at 
these receptors (Hohmann 2002, Szallasi and Blumberg 1999). The interactions at the level 
of the signal transduction pathway on the same synapses or at different synapses are both 
plausible explanations. The results suggest that TRPV1 receptor activation by AEA might 
complicate the interaction of CB1 and µ-opioid or adenosine receptors under these 
circumstances. These effects may change the release of both excitatory and inhibitory 
transmitters presynaptically from primary sensory neurons and/or postsynaptically from the 
interneurons, and they can modify activation of the projecting neurons as well.  
An important attribute of the present potentiation is the lack of side effects (except 
in the case of AEA applied in the highest dose), suggesting that combined drug delivery 
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can, in principle, serve to enhance the therapeutic ratio of the treatment. Furthermore, the 
coadministration of endogenous ligands might simulate the physiological behavior of the 
organism. In conclusion, EM1 and AEA cotreatment may be a beneficial combination for 
pain therapy, however, ADE and AEA cotreatment will presumably not be an ideal 
combination for inflammatory pain, but further studies are required in other pain models 
(e.g. neuropathy) to explore their interactions in pain which is induced by different 
mechanisms.  
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Pain sensitivity changes in schizophrenia models 
 
This part of the thesis suggests that social isolation for three weeks after weaning 
causes a long-lasting decrease in acute heat pain sensitivity, that is, single housing 
condition produced a significant increase in the pain threshold in tail-flick test at 48 °C, and 
there was also a trend toward significance at 52 °C, suggesting a more pronounced effect 
on the C-fiber-mediated nociception. These results suggest that the equilibrium of the 
nociceptive/antinociceptive systems might have changed for a long period of time in our 
models. 
It is well-known that housing conditions are an important factor contributing to 
modifications in pain perception in animals, and our result is in concordance with earlier 
data showing that juvenile isolation caused significant changes in pain sensitivity, which 
might be due to changes mainly in the number and activity of µ-opioid receptors (DeFeudis 
et al. 1976, Puglisi-Allegra and Oliverio 1983, Szikszay and Benedek 1989, Van den Berg 
et al. 1999b). However, Becker et al. have found that isolation caused hyperalgesia in hot-
plate test, while the threshold in tail root stimulation test did not change (Becker et al. 
2006). The differences may be explained by the diversity in the organization of the tests, 
that is, hot-plate test is mainly structured supraspinally, while tail-flick test is structured 
largely at the spinal level. Furthermore, Becker et al. used adult Sprague-Dawley animals, 
and the duration of isolation was shorter (2 vs. 3 weeks), while in the present experiment, 
juvenile Wistar rats were isolated or socially housed during weeks 4–6 of age, a period with 
high levels of social play (Pellis et al. 1997, Vanderschuren et al. 1997, Weiss and Feldon 
2001). In addition, Becker et al. used social isolation after ketamine or saline treatment; 
therefore, injections and social isolation were performed consecutively instead of parallel as 
in this work. Our work focused on the responses to heat stimuli therefore, discussion of 
functional significance is confined to this sensory modality. It is well-known that C- and 
A -fibers convey different modalities of pain, that is, myelinated heat nociceptors have 
higher threshold than unmyelinated fibers (Leem et al. 1993, Treede et al. 1998). 
Furthermore, they have different chemical phenotypes, different pharmacological 
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sensitivities, and play different roles in animal models of pain (Lu et al. 2004, Lumb 2002, 
Yeomans et al. 1996). In order to directly test the hypothesis that ketamine and/or social 
isolation may exert differential control of activity evoked by different classes of 
nociceptors, we applied tail-flick tests at both low and high temperatures. The current work 
demonstrates that social isolation differentially modulates reflexes evoked by myelinated 
vs. unmyelinated heat nociceptors. Thus, juvenile isolation not only attenuated responses 
significantly evoked by unmyelinated nociceptors, but it also slightly influenced myelinated 
nociceptor-induced responses. In this model, preferential inhibition of activity evoked by 
unmyelinated heat nociceptors would increase nociceptive threshold but maintain 
transmission of high-resolution input. The nociceptive responses to both high and low rates 
of skin heating are mediated by neuronal circuits in the spinal cord, but descending control 
of spinal nociception is a major determinant of pain sensitivity (Yeomans et al. 1996). 
Activation of neurons in the PAG significantly increases response thresholds to C-fibers 
but not those to A -fibers; furthermore, PAG lesion decreased the analgesic effect of social 
isolation suggesting that PAG mediates stress-induced analgesia (McMullan and Lumb 
2006, Wiedenmayer et al. 2000). Thus, a possible explanation for our data is that juvenile 
isolation developmentally alters the maturation of this descending inhibitory system 
resulting in C-fiber-mediated hypoalgesia. Similar to pain pathways, parallel magnocellular 
and parvocellular visual pathways exist, and recent results have shown that early-stage 
perceptual dysfunctions, which may reflect the abnormality of precortical magnocellular 
pathways, are related to schizophrenia in humans (Cimmer et al. 2006, Keri et al. 2005). 
In contrast to the isolation, subchronic ketamine treatment in young animals neither 
influenced the pain sensitivity nor enhanced the effect of social isolation. At a first glance, 
this result appears surprising with regard to the established role of NMDA receptors in pain 
mechanism; however, earlier studies also have shown that ketamine does not influence 
acute pain sensitivity (Joo et al. 2000, Klimscha et al. 1998). These observations are in 
agreement with a recent study showing that ketamine by itself does not influence heat pain 
sensitivity after subchronic administration (Becker et al. 2006). Thus, it seems that 
subchronic ketamine treatment could not reproduce the hypoalgesia characterized in 
schizophrenia, while social isolation can replicate it for a long time in tail-flick test, 
suggesting that this dose and/or duration of ketamine injections do not simulate the 
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schizophrenic hypoalgesia, thus NMDA function does not play a significant role in acute 
heat pain sensitivity changes in schizophrenia. Further experiments are needed to elucidate 
whether longer treatment and/or higher dose of ketamine could lead to more pronounced 
changes in the isolation-induced hypoalgesia. 
During the paw-withdrawal test, we did not find significant differences between the 
groups as regards the basal values; however, there was a trend toward significance in the 
effect of housing conditions, on the inflammatory pain sensation. Furthermore, we found an 
increased anti-hyperalgesic effect of 2 mg/kg morphine 5 weeks after both social isolation 
and ketamine treatment. The highly test-dependent nature of pain sensitivity changes 
supports the view that the mechanisms that modulate thermal nociceptive responses evoked 
from the tail and hindpaw are not uniform (Ackley et al. 2001). Furthermore, inflammation 
significantly increases the activity of both unmyelinated and myelinated fibers, thus we 
suppose that neither social isolation nor ketamine treatment could influence significantly 
these processes for this long period (5 weeks) during carrageenan-induced inflammation 
(Coggeshall et al. 2004). Becker et al. observed increased antinociception after morphine 
administration in isolated and ketamine treated animals, but not in the other groups. 
However, they measured the effect of morphine in acute pain tests (HP, tail-root 
stimulation) immediately after the isolation, which might lead to the observed differences. 
It has been shown that juvenile isolation caused region-specific increases in the number of 
µ-opioid receptor binding sites and a general upregulation of -receptors (Van den Berg et 
al. 1999a). Similarly, Becker et al. have found that the number of opioid receptor binding 
sites and the relative efficacy of μ-opioid receptors were increased in isolated and ketamine 
pretreated rats and isolation increased their activity, which might have contributed to the 
enhanced analgesic potency of morphine (Becker et al. 2006). The involvement of opioids 
in schizophrenia is a subject of controversial discussion. Whilst some investigators have 
found different concentrations and alterations in the number of binding sites and genetic 
polymorphisms, others have reported similar levels in schizophrenics and respective control 
populations (Danos et al. 2002, Gulya 1990, Zhang et al. 2004). Thus, it has been suggested 
that hypoalgesia might be due to changes in opioid functions in both schizophrenia and in 
isolated rat models. However, since neurotransmitters and their receptors (e.g., dopamine, 
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acetylcholine), which contribute to schizophrenia, also influence pain sensitivity, we should 
also be concerned about these systems (Altier and Stewart 1999, Sommer 2004). 
We observed a progressive increase in tail-flick latency in these young animals 
during our investigated period at both temperatures. Several studies have shown that 
juvenile organisms are hyperresponsive to cutaneous stimuli (Al Amin et al. 2004, Falcon 
et al. 1996). The tail-flick latency showed a progressive increase with age, where it 
increased after puberty and was maintained throughout adulthood (Al Amin et al. 2004). 
Changes in responsiveness to suprathreshold noxious stimuli involve maturation of both 
spinal and descending supraspinal structures. This work was not designed primarily to 
assess the effects of aging as the animals were tested over a short period only, while most 
of the studies reviewed by Gagliese and Melzack (2000) have their testing done over one or 
two years. However, we observed a difference in the pattern of increase of the tail-flick 
latencies between the two temperatures, that is, the A -fiber-mediated pain threshold 
increased faster, compared with the C-fiber-mediated pain sensation. The mechanisms 
underlying this difference are not completely understood, but are probably related to the 
different maturation of the central and spinal nociceptive mechanisms (Fitzgerald and 
Jennings 1999).  
In conclusion, these results show that juvenile isolation for three weeks produces a 
long-lasting decrease mainly in the C-fiber-mediated pain sensitivity, suggesting a selective 
disturbance in the different parallel sensory pathways. In addition, ketamine treatment did 
not produce effects on acute heat pain sensitivity, but potentiated the antihyperalgesic effect 
of morphine. Since both social isolation and NMDA treatment are well-known animal 
models of schizophrenia, our results showed that juvenile isolation but not ketamine 
administration could simulate hypoalgesia associated with this disease. However, ketamine 
treatment also influenced the potency of morphine, suggesting that this model also shows 
some effects on the nociceptive mechanisms. 
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General Conclusions 
 
1. We have found that the combination of the endogenous ligands EM1 and AEA 
produced additive antinociceptive interaction, thus their combination may provide a 
new and beneficial combination for pain therapy with potentially fewer side effects 
at spinal level.  
 
2. Neither ADE nor CAFF by themselves potentiated the antinociceptive effect of 
AEA at spinal level in our pain models, and even some kind of antagonism could be 
found. Further, the coadministration of ADE and CAFF moderately modified the 
antinociceptive potential of AEA. Thus, ADE and AEA cotreatment will 
presumably not be a beneficial combination for inflammatory pain, but further 
studies are required in other pain models (e.g. neuropathy) to explore their 
interactions in pain which is induced by different mechanisms.  
 
3. We wish to draw the attention to the rapidly evolving recognition that the 
endogenous ligands may exert effects on several receptors and/or systems, therefore 
we consider that their in vivo interaction must be very complex and the net outcome 
after their coadministration could not been predicted from the in vitro results.  
 
4. We firstly demonstrated that juvenile isolation for three weeks (but not ketamine 
treatment) produces a long-lasting decrease mainly in the C-fiber-mediated acute 
heat pain sensitivity, suggesting a selective disturbance in the different parallel 
sensory pathways. In addition, both treatments and their combination potentiated 
the antihyperalgesic effect of morphine. Since both social isolation and NMDA 
treatment are well-known animal models of schizophrenia, our results showed that 
these paradigms can disturb the balance between the endogenous pro- and 
antinociceptive mechanisms.  
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